Ocanacatib antifracture efficacy and saftey in postmenopausal women with osteoporosis: results from the phase III long-term adonacatib fracture trial (LOFT)McClung, A. Lombardi, Awc Kung et al.|Open Repository and Bibliography (University of Liège)|2015Cited by 3
Safety and Tolerability of Odanacatib Therapy in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT)Socrates E. Papapoulos, Deborah M. Gurner, Michael R. McClung et al.|Data Archiving and Networked Services (DANS)|2014Cited by 3
Safety and tolerability of odanacatib therapy in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trialSocrates E. Papapoulos, Deborah M. Gurner, McClung et al.|Open Repository and Bibliography (University of Liège)|2014Cited by 2
Reduction in the risk of back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysisJean‐Yves Reginster, John H. Krege, Michael C. Nevitt et al.|Open Repository and Bibliography (University of Liège)|2005Cited by 0